FDG PET in Neurological Manifestations of COVID-19.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 38557407.
- Also identified by DOI 10.1097/RLU.0000000000005187.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Both the central and peripheral nervous systems can be affected in COVID-19. Although MRI is the primary investigative tool for neurological imaging, FDG PET may show additional areas of involvement in the brain in the form of regional hypometabolism or hypermetabolism, secondary to synaptic dysfunction and electrical or glial activation. We present a case series of 4 patients who had neurological symptoms attributable to COVID-19 infection with abnormalities in the brain FDG PET scan.
Medical subject headings
- COVID-19
- Fluorodeoxyglucose F18
- Nervous System Diseases
- Positron-Emission Tomography